Please sign in to follow a disease.
Syndax Pharmaceuticals
Clinical trials sponsored by Syndax Pharmaceuticals, explained in plain language.
A biopharmaceutical company developing cancer therapies, including treatments for leukemia and other malignancies.
Not investment advice. Company information is shown for context only. Clinical trials frequently fail.
Advertising disclosure. Links marked "(ad)" go to partners we have a commercial relationship with, either a broker where you can trade or a stock-research service, and we may earn a commission if you open an account or subscribe. This never affects what is shown here.
Upcoming readouts
Trials from this sponsor expected to report results within the next 12 months.
- New drug shows promise in slowing lung scarring Results expected Sep 2026 (estimated) May already have reported ↗
- New hope for Hard-to-Treat leukemia: targeted pill combined with chemotherapy enters human trials Results expected Feb 2027 (estimated) May already have reported ↗
-
New hope for tough leukemias: experimental pill targets genetic weakness
Disease control Recruiting nowThis study tests an oral drug called revumenib in people with certain types of leukemia that have relapsed or not responded to standard therapy. The trial has two parts: first, finding the best dose, then testing that dose in four groups based on leukemia type. About 447 particip…
Phase 1/2 • Sponsor: Syndax Pharmaceuticals • Aim: Disease control
Last updated Sep 18, 2026 00:00 UTC
-
New drug combo aims to beat tough leukemia
Disease control Recruiting nowThis phase 3 trial tests whether adding the drug revumenib to standard intensive chemotherapy helps people with newly diagnosed acute myeloid leukemia (AML) that has a specific genetic change (NPM1 mutation). About 468 participants will receive either revumenib or a placebo along…
Phase 3 • Sponsor: Syndax Pharmaceuticals • Aim: Disease control
Last updated Aug 30, 2026 00:00 UTC
-
New hope for GVHD patients who failed other treatments
Disease control Recruiting nowThis study tests a drug called axatilimab in people with chronic graft-versus-host disease (cGVHD), a complication after a stem cell transplant where donor cells attack the patient's body. Participants must have tried at least two other treatments without success. The goal is to …
Phase 2 • Sponsor: Syndax Pharmaceuticals • Aim: Disease control
Last updated Jun 27, 2026 14:00 UTC